MA51060A - Formulations de compositions de vaccin contre le virus de la dengue - Google Patents

Formulations de compositions de vaccin contre le virus de la dengue

Info

Publication number
MA51060A
MA51060A MA051060A MA51060A MA51060A MA 51060 A MA51060 A MA 51060A MA 051060 A MA051060 A MA 051060A MA 51060 A MA51060 A MA 51060A MA 51060 A MA51060 A MA 51060A
Authority
MA
Morocco
Prior art keywords
vaccine composition
dengue virus
virus vaccine
composition formulations
formulations
Prior art date
Application number
MA051060A
Other languages
English (en)
Inventor
Akhilesh Bhambhani
Jeffrey Thomas Blue
Erin J Green-Trexler
Lynne Ann Isopi
Morrisa Jones
Sherrie-Ann P Martin
Heidi Joanne Pixley
Michael S Ryan
Justin Stanbro
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA51060A publication Critical patent/MA51060A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA051060A 2017-12-07 2018-12-03 Formulations de compositions de vaccin contre le virus de la dengue MA51060A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762595842P 2017-12-07 2017-12-07

Publications (1)

Publication Number Publication Date
MA51060A true MA51060A (fr) 2021-03-17

Family

ID=66750326

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051060A MA51060A (fr) 2017-12-07 2018-12-03 Formulations de compositions de vaccin contre le virus de la dengue

Country Status (26)

Country Link
US (3) US20200390877A1 (fr)
EP (1) EP3720487A4 (fr)
JP (1) JP7042341B2 (fr)
KR (1) KR102494651B1 (fr)
CN (2) CN117752780A (fr)
AU (1) AU2018381213B2 (fr)
BR (1) BR112020011205A8 (fr)
CA (1) CA3083772A1 (fr)
CL (1) CL2020001463A1 (fr)
CO (1) CO2020006836A2 (fr)
CR (1) CR20200242A (fr)
DO (1) DOP2020000098A (fr)
EA (1) EA202091398A1 (fr)
EC (1) ECSP20032084A (fr)
GE (2) GEAP202315384A (fr)
IL (2) IL274897B2 (fr)
JO (2) JOP20200140B1 (fr)
MA (1) MA51060A (fr)
MX (1) MX2020005857A (fr)
NI (1) NI202000039A (fr)
PE (1) PE20210654A1 (fr)
PH (1) PH12020550734A1 (fr)
SG (1) SG11202005251VA (fr)
UA (1) UA129245C2 (fr)
WO (1) WO2019112921A1 (fr)
ZA (2) ZA202002999B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020011205A8 (pt) 2017-12-07 2023-02-07 Merck Sharp & Dohme Formulações de composições de vacina contra o vírus da dengue
WO2022094816A1 (fr) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Formulation solide
US20250235420A1 (en) * 2021-10-20 2025-07-24 Solventum Intellectual Properties Company Phosphate and Arginine Containing Compositions and the Delivery of Such Compositions for Virulence Suppression
WO2024073362A2 (fr) * 2022-09-29 2024-04-04 Board Of Regents, The University Of Texas System Procédés et compositions pour le transport, le stockage et l'administration d'acides nucléiques et d'autres molécules
CN120152737A (zh) 2022-10-18 2025-06-13 武田疫苗股份有限公司 登革热疫苗制剂
WO2024118542A1 (fr) 2022-11-28 2024-06-06 Takeda Vaccines, Inc. Procédé de détermination quantitative d'un monomère d'albumine sérique humaine dans des compositions pharmaceutiques contenant des virus
CN121218977A (zh) * 2023-05-17 2025-12-26 勃林格殷格翰国际有限公司 用以稳定基于病毒的治疗剂的调配物
AU2024273927A1 (en) * 2023-05-17 2025-11-06 Boehringer Ingelheim International Gmbh Formulations to stabilize virus-based therapeutics
WO2025027616A1 (fr) * 2023-08-01 2025-02-06 Serum Institute Of India Private Limited Compositions de vaccin viral lyophilisé et leur méthode de fabrication
WO2025132735A1 (fr) * 2023-12-20 2025-06-26 Intervet International B.V. Composition lyophilisée contenant des agents pathogènes atténués vivants, procédé de préparation d'une composition lyophilisée, vaccin et procédé de vaccination d'un animal hôte
CN118853589B (zh) * 2024-07-03 2025-04-01 中国科学院武汉病毒研究所 一种黄热病毒疫苗株3’utr缺失突变体的拯救及在制备减毒活疫苗中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233770D1 (de) 1991-09-19 2009-10-29 Us Health Chimäre und/oder wachstumgehemmte Flaviviren
FR2702660B1 (fr) * 1993-03-17 1995-05-24 Karl Simpson Compositions thérapeutiques stabilisées et leur procédé de préparation.
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
US6190859B1 (en) 1995-04-17 2001-02-20 The United States Of America As Represented By The Secretary Of The Army Method and kit for detection of dengue virus
US6432411B1 (en) 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP2290108B1 (fr) 2001-05-22 2014-07-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Mise au point de mutations utiles pour l'atténuation des virus de la dengue et des virus de la dengue chimériques
AU2003267943C1 (en) * 2002-02-26 2009-05-21 Altravax, Inc. Novel flavivirus antigens
PL377028A1 (pl) * 2002-03-26 2006-01-23 Immunex Corporation Sposoby wykorzystania ligandu Flt-3 w procedurach immunizacyjnych
HUE037330T2 (hu) 2002-05-03 2018-08-28 The Government Of The Us Secretary Department Of Health And Human Services rDEN3/4delta30(ME), rDEN2/4delta30(ME) vagy rDEN1/4delta30(ME) rekombináns kiméra dengue virus, amely 30 nukleotidos deléciót tartalmaz (delta 30) a 4-es típusú dengue genom 3' nem-transzlálódó régiójában, ahol a szóban forgó 30 nukleotidos deléció megfelel a TL2 nyél-hurok szerkezetnek
US20050123550A1 (en) 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
RU2007129840A (ru) 2005-01-05 2009-02-20 Филадельфия Хелт Энд Эдьюкейшн Корпорейшн Д/Б/А Дрексел Юниверсити Колледж Оф Медисин (Us) Средства доставки, биологически активные вещества и вирусные вакцины
CA2612047C (fr) 2005-06-24 2015-05-12 Intervet International B.V. Vaccins chimeres inactives et leurs procedes d'utilisation
CN101296705A (zh) * 2005-10-04 2008-10-29 阿尔克-阿贝洛有限公司 固体疫苗制剂
AU2006299310A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
EP2589602B1 (fr) 2006-08-15 2016-04-06 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Développement de composants de vaccins du virus de la dengue
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
PT2144998T (pt) 2007-04-06 2017-04-07 Takeda Vaccines Inc Métodos e composições para vírus vivos atenuados
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
CA2738024A1 (fr) * 2008-09-24 2010-04-01 Medimmune, Llc Procedes de purification de virus
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
EP2405945A4 (fr) 2009-03-13 2012-09-12 Lentigen Corp Vaccins à vecteurs rétroviraux non intégrants
GB201002419D0 (en) * 2010-02-12 2010-03-31 Isis Innovation Stable live vaccine formulations
KR20130138789A (ko) 2010-10-29 2013-12-19 머크 샤프 앤드 돔 코포레이션 재조합 서브유닛 뎅기 바이러스 백신
PH12013502442A1 (en) 2011-05-26 2018-03-21 Glaxo Smithkline Biologicals Sa Inactivated dengue virus vaccine
WO2013119856A1 (fr) 2012-02-07 2013-08-15 Infectious Disease Research Institute Formulations d'adjuvant amélioré comprenant des agonistes de tlr4 et leurs procédés d'utilisation
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US9974850B2 (en) * 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
US9254332B2 (en) * 2013-03-15 2016-02-09 Arecor Limited Stable aqueous formulations of adenovirus vectors
MY187896A (en) 2013-06-21 2021-10-27 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
EP3057612B1 (fr) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Procédé d'obtention de formulations de vaccin séchées thermostables
US10588957B2 (en) 2013-10-25 2020-03-17 Leukocare Ag Method for the production of stabile vaccines
US20160310412A1 (en) 2013-12-16 2016-10-27 Takeda Pharmaceutical Company Limited Microneedle
IL246456B2 (en) * 2013-12-31 2024-06-01 Access To Advanced Health Inst Formulations will be assembled into a single vial
WO2015130157A1 (fr) 2014-02-28 2015-09-03 Universiti Malaya Amélioration de la production du virus de la dengue
MX383329B (es) 2014-12-22 2025-03-13 Merck Sharp & Dohme Llc Composiciones de vacuna para el virus del dengue y metodos de uso de las mismas.
CN107949636B (zh) * 2015-06-04 2021-11-09 香港大学 活减毒病毒以及生产和使用方法
EP3310384A1 (fr) * 2015-06-17 2018-04-25 CureVac AG Composition de vaccin
US10004795B2 (en) 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
MY200888A (en) * 2015-09-30 2024-01-22 Panacea Biotec Ltd Stable Live Attenuated Recombinant Dengue Vaccine
WO2017109698A1 (fr) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Formulation immunogène
CN109311986A (zh) 2016-03-25 2019-02-05 威特拉公司 登革热病毒抗体分子的制剂
MY192806A (en) * 2016-04-13 2022-09-09 Takeda Vaccines Inc Compositions and methods of vaccination against dengue virus in children and young adults
JPWO2017179726A1 (ja) * 2016-04-15 2019-05-23 国立大学法人大阪大学 中和抗体を誘導するが感染増強抗体の誘導を抑制するデングワクチン抗原
TW202309276A (zh) 2016-08-03 2023-03-01 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法
EP3532093A1 (fr) 2016-09-19 2019-09-04 Vaxess Technologies, Inc. Formulations de vaccin présentant une stabilité accrue
EP3601544A4 (fr) 2017-03-30 2021-01-27 Merck Sharp & Dohme Corp. Addition de nucléases directement à une culture cellulaire pour faciliter la digestion et la clairance d'acides nucléiques de cellules hôtes
PE20210106A1 (es) 2017-10-16 2021-01-19 Serum Institute Of India Pvt Ltd Composiciones de vacuna estables que comprenden inter alia un flavivirus recombinante vivo atenuado y proceso para la preparacion de las mismas
BR112020011205A8 (pt) * 2017-12-07 2023-02-07 Merck Sharp & Dohme Formulações de composições de vacina contra o vírus da dengue

Also Published As

Publication number Publication date
JOP20200140A1 (ar) 2022-10-30
IL274897B2 (en) 2025-03-01
PH12020550734A1 (en) 2021-04-19
CL2020001463A1 (es) 2020-09-25
IL316312A (en) 2024-12-01
US20230061673A1 (en) 2023-03-02
US11883480B2 (en) 2024-01-30
MX2020005857A (es) 2020-09-09
WO2019112921A1 (fr) 2019-06-13
DOP2020000098A (es) 2020-08-31
US12208135B2 (en) 2025-01-28
CN111447947B (zh) 2024-01-12
ZA202002999B (en) 2026-01-28
US20200390877A1 (en) 2020-12-17
IL274897A (en) 2020-07-30
SG11202005251VA (en) 2020-07-29
CR20200242A (es) 2020-07-17
JP2021505588A (ja) 2021-02-18
PE20210654A1 (es) 2021-03-31
AU2018381213A1 (en) 2020-06-11
CA3083772A1 (fr) 2019-06-13
EP3720487A4 (fr) 2026-01-14
UA129245C2 (uk) 2025-02-26
CN117752780A (zh) 2024-03-26
BR112020011205A2 (pt) 2020-11-17
IL274897B1 (en) 2024-11-01
JOP20250145A1 (ar) 2025-06-18
CO2020006836A2 (es) 2020-06-19
ZA202407615B (en) 2025-04-30
KR20200096272A (ko) 2020-08-11
ECSP20032084A (es) 2020-08-31
BR112020011205A8 (pt) 2023-02-07
AU2018381213B2 (en) 2022-03-17
KR102494651B1 (ko) 2023-01-31
EA202091398A1 (ru) 2020-09-01
GEP20237539B (en) 2023-09-11
EP3720487A1 (fr) 2020-10-14
CN111447947A (zh) 2020-07-24
JP7042341B2 (ja) 2022-03-25
NI202000039A (es) 2020-09-24
GEAP202315384A (en) 2023-05-25
US20240131144A1 (en) 2024-04-25
JOP20200140B1 (ar) 2025-10-01

Similar Documents

Publication Publication Date Title
MA51060A (fr) Formulations de compositions de vaccin contre le virus de la dengue
EP3668541A4 (fr) Formulations de vaccin pneumococcique conjugué
EP3585803A4 (fr) Formulations de vaccin pneumococcique conjugué
IL257800A (en) Immune compositions with improved stability and immunogenicity
EP3641771A4 (fr) Compositions pharmaceutiques
LT3362049T (lt) Kamptotecino farmacinių kompozicijų stabilizavimas
MA45381A (fr) Formulation de vaccin contre le vih
SG11201701256RA (en) Vaccine compositions against dengue virus diseases
IL280332A (en) A preparation containing a flu vaccine
SI3435980T1 (sl) Fiziološko uravnotežene injektabilne formulacije fosnetupitanta
EP3010536A4 (fr) Compositions de vaccin contre le virus de la dengue, et leurs procédés d'utilisation
EP3344293A4 (fr) Compositions de vaccin stabilisés de vlp
SG11202009147UA (en) Vaccine compositions
GB201801566D0 (en) Methods and compositions for nanormulsion vaccine formulations
EP4387592A4 (fr) Compositions vaccinales
LT3389633T (lt) Farmacinės kompozicijos, apimančios fenilaminopirimidino darinį
ME03033B (fr) Peptides dérivés de l'ezrine et compositions pharmaceutiques correspondantes
EP3305328A4 (fr) Composition protectrice de vaccin non gélatineuse et vaccin contre la grippe vivant atténué
EP3236997A4 (fr) Compositions de vaccin contre le virus de la dengue et procédés pour les utiliser
GB2562241B (en) Vaccine compositions
EP3939607A4 (fr) Vaccin contre le virus de la dengue
EP3764991A4 (fr) Composition vaccinale
DK3638211T3 (da) Farmaceutiske sammensætninger med forsinket vedvarende frigivelse
EP3706731A4 (fr) Formulations améliorées de médicaments
EP3826672A4 (fr) Vaccin contre le virus zika